Table 2. Results for Site Prediction.
| Predicted site | No. (%) | Treatment | |
|---|---|---|---|
| Enrolled patients (n = 111) | Patients in the efficacy analysis (n = 97) | ||
| Lung | 21 (18.9) | 21 (21.6) | Platinum + taxane (n = 9), platinum + PEM (n = 8), EGFR-TKI (n = 4) |
| Liver | 20 (18.0) | 15 (15.5) | Sorafenib |
| Kidney | 16 (14.4) | 15 (15.5) | VEGF inhibitor (n = 14), mTOR inhibitor (n = 1) |
| Colon/rectum | 14 (12.6) | 12 (12.4) | FOLFOX/CapeOX/SOX plus bevacizumab (n = 6), CapeOX (n = 2), FOLFOXIRI (n = 1), FOLFOXIRI + bevacizumab (n = 1) FOLFIRI + panitumumab (n = 1), S-1 + bevacizumab (n = 1) |
| Ovary | 9 (8.1) | 7 (7.2) | CBDCA + PTX (n = 5), CBDCA + PTX + bevacizumab (n = 2) |
| Biliary tract (gallbladder, bile ducts) | 7 (6.3) | 7 (7.2) | CDDP + GEM |
| Breast | 6 (5.4) | 5 (5.2) | AC (n = 2), PTX + bevacizumab (n = 2), DTX (n = 1) |
| Germ cell | 5 (4.5) | 5 (5.2) | BEP (n = 4), ICE (n = 1) |
| Cervix | 3 (3.6) | 3 (3.1) | CBDCA + PTX |
| Pancreas | 3 (2.7) | 2 (2.1) | GEM + nab-PTX |
| Lymphoma | 2 (1.8) | 1 (1.0) | CHOP |
| Head and neck | 2 (1.8) | 1 (1.0) | FP + cetuximab |
| Urothelium | 1 (0.9) | 1 (1.0) | CDDP + GEM |
| Stomach | 1 (0.9) | 1 (1.0) | S-1 |
| Prostate | 1 (0.9) | 1 (1.0) | Leuprorelin + bicalutamide |
Abbreviations: AC, Adriamycin (doxorubicin) and cyclophosphamide; BEP, bleomycin, etoposide, and cisplatin; CapeOX, oxaliplatin and capecitabine; CBDCA, carboplatin; CDDP, cisplatin; CHOP, Adriamycin (doxorubicin), cyclophosphamide, Oncovin (vincristine), and prednisone; DTX, docetaxel; EGFR-TKI, epidermal growth factor receptor–tyrosine kinase inhibitor; FOLFIRI, irinotecan, infusional and bolus 5-fluorouracil, and leucovorin; FOLFOXIRI, oxaliplatin, irinotecan, infusional and bolus 5-fluorouracil, and leucovorin; FOLFOX, oxaliplatin, infusional and bolus 5-fluorouracil, and leucovorin; FP, 5-fluorouracil and cisplatin; GEM, gemcitabine; ICE, ifosfamide, cisplatin, and etoposide; mTOR, mammalian target of rapamycin; nab-PTX, albumin-bound paclitaxel nanoparticle; PEM, pemetrexed; PTX, paclitaxel; SOX, oxaliplatin and S-1; S-1, tegafur, gimeracil, and oteracil potassium; VEGF, vascular endothelial growth factor.